News

November 11, 2025

Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development

October 9, 2025

Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to its Board of Directors      

September 10, 2025

Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases

January 8, 2025

Odyssey Therapeutics Appoints Jason Haas as Chief Financial Officer

October 28, 2024

Odyssey Therapeutics and Terray Therapeutics Enter Strategic Collaboration to Jointly Discover and Develop First-in-Class Transcription Factor Therapies